The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Akero Therapeutics Inc shares valued at $576,035 were sold by Young Jonathan on Sep 02 ’25. At $46.08 per share, Young Jonathan sold 12,500 shares. The insider’s holdings dropped to 197,484 shares worth approximately $8.7 million following the completion of this transaction.
Also, Young Jonathan sold 12,500 shares, netting a total of over 597,326 in proceeds. Following the sale of shares at $47.79 each, the insider now holds 197,484 shares.
Before that, Cheng Andrew had sold 30,000 shares from its account. In a trade valued at $1,457,596, the President and CEO traded Akero Therapeutics Inc shares for $48.59 each. Upon closing the transaction, the insider’s holdings decreased to 30,000 shares, worth approximately $21.61 million.
Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in early August. As of January 30, 2025, BofA Securities has increased its “Neutral” rating to a “Buy” for AKRO. Earlier on January 27, 2025, H.C. Wainwright resumed its rating. Their recommendation was “a Buy” for AKRO stock.
Analyzing AKRO Stock Performance
On last trading session, Akero Therapeutics Inc [NASDAQ: AKRO] plunged -3.49% to $44.03. The stock’s lowest price that day was $43.09, but it reached a high of $46.18 in the same session. During the last five days, there has been a drop of approximately -8.63%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 61.87%. Shares of the company reached a 52-week high of $58.40 on 01/27/25 and a 52-week low of $21.34 on 01/14/25.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
According to the 24-hour chart, there is a support level at 42.68, which, if violated, would cause prices to drop to 41.33. In the upper region, resistance lies at 45.78. The next price resistance is at 47.53. RSI (Relative Strength Index) is 33.37 on the 14-day chart, showing neutral technical sentiment.
Is Akero Therapeutics Inc subject to short interest?
Stocks of Akero Therapeutics Inc saw a sharp rise in short interest on 2025-08-15 jumping by 1.06 million shares to 9.22 million. Data from Yahoo Finance shows that the short interest on 2025-07-15 was 8.16 million shares. A jump of 11.47% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.36 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.36.
Which companies own the most shares of Akero Therapeutics Inc (AKRO)?
In terms of Akero Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 72 in the next 12 months, up nearly 57.83% from the previous closing price of $45.62. Analysts anticipate Akero Therapeutics Inc stock to reach 72 by 2025, with the lowest price target being 72. In spite of this, 4 analysts ranked Akero Therapeutics Inc stock as Buy at the end of 2025. On November 18, 2024, Citigroup assigned a price target of “a Buy” to the stock and initiated coverage with a $65.
